Literature DB >> 445447

Competitive binding radioassay for 5-fluorodeoxyuridine 5'-monophosphate in tissues.

D S Murinson, T Anderson, H S Schwartz, C E Myers, B A Chabner.   

Abstract

A competitive binding radioassay has been developed for 5-fluorodeoxyuridine 5'-monophosphate, based on the tight binding of this potent inhibitor to thymidylate synthetase (EC 2.1.1.45). Unbound ligand may be separated from that bound to enzyme by precipitating the intact inhibitor-enzyme complex with trichloroacetic acid. Scatchard plot analysis using a two-site model for binding yielded apparent dissociation constants of 1.2 x 10(-11) and 1.7 x 10(-10) M from a least-squares computer fit of the data. 5-Fluorodeoxyuridine 5'-monophosphate could be detected in the range of 0.02 to 2.0 pmol with no apparent interference by other substances. Assay of 5-fluorodeoxyuridine 5'-monophosphate levels in L1210 ascites tumor following 5-fluorouracil in vivo revealed peak levels occurring within the first hr with a subsequent disappearance half-life of 3.9 hr. Close agreement was found between the previously described enzyme inhibition assay and the more rapid and sensitive competitive binding method.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 445447

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  4 in total

1.  Inhibition of thymidylate synthase by the diastereoisomers of leucovorin.

Authors:  P P Lee; R L Schilsky
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  19F NMR studies of the binding of 5-fluoro-2'-deoxyuridylate to thymidylate synthase.

Authors:  M J Beckage; M Blumenstein; R L Kisliuk
Journal:  Mol Cell Biochem       Date:  1980-08-29       Impact factor: 3.396

3.  Competitive binding radioassay for the determination of 5-fluorodeoxyuridine and 5-fluorodeoxyuridine-5'-monophosphate levels in plasma and tumor tissue.

Authors:  S Miyata; H Mikami; M Tai; T Hori; H Fujita
Journal:  Jpn J Cancer Res       Date:  1991-06

4.  Enhanced antitumor effect of 5'-deoxy-5-fluorouridine by oral administration with L-cysteine.

Authors:  M Iigo; Y Nakajima; E Araki; A Hoshi
Journal:  Jpn J Cancer Res       Date:  1989-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.